Filing Details
- Accession Number:
- 0001382963-17-000172
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-10-27 14:00:24
- Reporting Period:
- 2017-10-03
- Accepted Time:
- 2017-10-27 14:00:24
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1460702 | Ritter Pharmaceuticals Inc | RTTR | Pharmaceutical Preparations (2834) | 263474527 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1631671 | J Andrew Ritter | Ritter Pharmaceuticals, Inc. 1880 Century Park East, #1000 Los Angeles CA 90067 | President | No | Yes | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2017-10-03 | 187,500 | $0.00 | 1,004,772 | No | 4 | P | Indirect | By Stonehenge Partners LLC |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | P | Indirect | By Stonehenge Partners LLC |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Warrants (Right to Buy) | Acquisiton | 2017-10-03 | 187,500 | $0.00 | 187,500 | $0.44 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 187,500 | 2017-10-03 | 2022-10-03 | No | 4 | P | Indirect |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 6,250 | Direct |
Footnotes
- Stonehenge Partners LLC ("Stonehenge") purchased 187,500 Class A Units of the Issuer, consisting of 187,500 shares of common stock and warrants to purchase 187,500 shares of common stock, in the Issuer's October 2017 public offering at the public offering price of $0.40 per Class A Unit. The shares of common stock and warrants that are part of the Class A Units sold to Stonehenge in the public offering were immediately separable and were issued separately in the offering.
- As a managing partner of Stonehenge, the Reporting Person may be deemed the beneficial owner of these securities. The Reporting Person expressly disclaims beneficial ownership over these securities except to the extent of his pecuniary interest therein.
Billionaire Hedge Funds
